The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...

The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release. Compared ...

On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages ...

Studies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations “Exact Sciences’ research at ACG 2025 ...

(NEXSTAR) — An unexpected delivery at your door may not always be an unwelcome surprise — just ask one Kentucky boy about the thousands of dollars worth of lollipops that arrived at his home earlier ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

Edgewood, Ky.-based provider network St. Elizabeth Physicians has added additional drop-off locations for patients prescribed the Cologuard test. The new drop-off points are intended to improve ...

Anne grew up in a small farm town in southeast Nebraska, where her upbringing was filled with lessons on problem solving, teamwork and the importance of giving back. These qualities have carried her ...

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250922874822/en/ Horror icon Matthew Lillard is teaming ...